AbbVie

@abbvie · Global · joined 21 Mar 2012

Official global handle sharing the latest news about our company, science & people. Review our guidelines: https://t.co/pvWvxd2VWF

79 299Followers

462Following

8 801Posts total

7.8KViews on collected posts

Neueste Beiträge

AbbVie@abbvie4 Sep

Personalized care starts when a patient’s voice is heard. For Johannes, this means open dialogue with his care team to align choices with his priorities. This #WorldLeukemiaDay, we advocate for reciprocal communication that empowers patients to take an active role in their care. 340 views · 0 likes · 0 reposts · 0 replies Open on X →

AbbVie@abbvie3 Sep

New topline results are available from our Phase 3 study in patients with relapsed/refractory #MultipleMyeloma (RRMM), and we look forward to sharing the full data at this year’s @Myeloma_Society Annual Meeting. Read more: https://t.co/Qx1rjb26cS #IMS26 https://t.co/vZsf2ycn9n 1.3K views · 1 likes · 1 reposts · 3 replies Open on X →

AbbVie@abbvie3 Sep

Apogee Therapeutics is now part of AbbVie. This builds on our decades of #immunology leadership and adds to our diverse pipeline focused on elevating the standard of care for patients. Learn more: https://t.co/HTGUgyXkrX $ABBV https://t.co/0ZNmFUIV0G 1.5K views · 3 likes · 0 reposts · 1 replies Open on X →

AbbVie@abbvie29 Aug

@abbvie @EMA_News Help me. I need ur medicine 11 views · 0 likes · 0 reposts · 0 replies Open on X →

AbbVie@abbvie27 Aug

JUST IN: Learn about our submission to the @EMA_News for subcutaneous induction of one of our medicines in adults with moderately to severely active #CrohnsDisease: https://t.co/n22gi2cLPB https://t.co/CmbncEnHvH 1.7K views · 6 likes · 0 reposts · 1 replies Open on X →

AbbVie@abbvie24 Aug

@abbvie @IASLC I started taking Skyrizi...took my 2nd loading dose about mid May, my skin is clear and the psoriatic arthritis in my hands has improved... joint pain relief took a bit longer to achieve but my hands feel a lot better, thanks AbbVie 👍 28 views · 0 likes · 0 reposts · 0 replies Open on X →

AbbVie@abbvie21 Aug

[Video description: On-screen text reads, "Oncology News"] 541 views · 1 likes · 1 reposts · 0 replies Open on X →

AbbVie@abbvie21 Aug

At this year's @IASLC's World Conference on Lung Cancer, we're sharing new data across lung cancer, including #NSCLC and #SCLC. Read more: https://t.co/gfcIYgB0cd #WCLC26 https://t.co/OVtAF9AU8f 2.4K views · 6 likes · 1 reposts · 2 replies Open on X →

Im Vergleich zu Konten gleicher Größe

8 Beiträge aus den letzten 90 Tagen, verglichen mit der Größenklasse 10K–100K Follower. liegt bei Reichweite und Interaktion unter vergleichbaren Konten.

Medianaufrufe917dieses Konto924Median für 10K–100K

Reichweite, %1.16%dieses Konto3.62%Median für 10K–100K

Interaktion, %0.32%dieses Konto1.52%Median für 10K–100K

Kennzahl	Dieses Konto	Median für 10K–100K	Verhältnis
Medianaufrufe pro Beitrag	917	924	0.99×
Reichweite (Aufrufe ÷ Follower)	1.16%	3.62%	0.32×
Interaktionsrate	0.32%	1.52%	0.21×

Weitere Konten dieser Größe → Mit einem anderen Konto vergleichen → Wie diese Vergleichswerte entstehen →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

2.4K21 Aug

541

2824 Aug

1.7K27 Aug

1129 Aug

1.5K3 Sep

1.3K

3404 Sep

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.42%21 Aug

0.37%

0.00%24 Aug

0.41%27 Aug

0.00%29 Aug

0.26%3 Sep

0.46%

0.00%4 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes58.6%17 in total

Reposts10.3%3 in total

Replies24.1%7 in total

Quotes6.9%2 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.